Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Despite the promising efficacy of immune checkpoint blockade (ICB) in treating many types of cancers, the clinical benefits have often been restricted by the low objective response rates and systemic immune-related adverse events. Here, a bioresponsive ICB treatment is developed based on the reactive oxygen species (ROS)-sensitive protein complex for controlled sequential release of anti- "don't eat me" signal antibody (aCD47) and antiprogrammed cell death protein 1 (aPD1), by leveraging the abundant ROS in the tumor microenvironment (TME). These protein complexes can also act as scavengers of ROS in the TME to reverse the immunosuppressive responses, thereby enhancing antitumor efficacy in vivo. In a melanoma cancer model, the synergistic antitumor efficacy was achieved, which was accompanied by enhanced T cell immune responses together with reduced immunosuppressive responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
Self-citationImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Beyond oxidative stress: an immunologist's guide to reactive oxygen species
Nathan, C., & Cunningham-Bussel, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3423 · Cited by 1,619
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Cited by
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Peng, S., Xiao, F., Chen, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202103836 · Cited by 441
Responsive Exosome Nano-bioconjugates for Synergistic Cancer Therapy
Nie, W., Wu, G., Zhang, J., Huang, L., Ding, J., Jiang, A., Zhang, Y., Liu, Y., Li, J., Pu, K., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201912524 · Cited by 376
Molecular and nanoengineering approaches towards activatable cancer immunotherapy
Zhang, C., & Pu, K. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00773c · Cited by 302
Activatable Polymer Nanoenzymes for Photodynamic Immunometabolic Cancer Therapy
Zeng, Z., Zhang, C., Li, J., Cui, D., Jiang, Y., & Pu, K. (2021) · Advanced Materials · doi:10.1002/adma.202007247 · Cited by 276
Metadata
- Authors
- Chen, Q., Chen, G., Chen, J., Shen, J., Zhang, X., Wang, J., Chan, A., & Gu, Z.
- Venue
- Nano Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-07-11
- Volume
- 19
- Issue
- 8
- Pages
- 4879-4889
- ISSN
- 1530-6984 (ISSN-L)
- 1530-6992
- OpenAlex
- W2956287834
- Cited by
- 122
- References
- 13
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy. https://app.cochat.ai/papers/10.1021/acs.nanolett.9b00584
- The paper
- Chen, Q., Chen, G., Chen, J., Shen, J., Zhang, X., Wang, J., Chan, A., & Gu, Z. (2019). Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.9b00584
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.